Unisafe Bioscience Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 31 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 22.65%
- Profit Growth 172.51%
- Ebitda 34.88%
- Net Worth 6.42%
- Total Assets 32.25%
About Unisafe Bioscience
Unisafe Bioscience Private Limited (UBPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 15 April 1993 and has a history of 31 years and nine months. Its registered office is in Ahmedabad, Gujarat, India.
The Corporate was formerly known as Crystal Formulations Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Shabnam Rangwala and Zainab Fatepurwala serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230GJ1993PTC019290
-
Company No.
019290
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
15 Apr 1993
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Unisafe Bioscience?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shabnam Rangwala
|
Director | 01-Oct-2024 | Current |
|
Zainab Fatepurwala
|
Additional Director | 01-Oct-2024 | Current |
Financial Performance of Unisafe Bioscience.
Unisafe Bioscience Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 22.65% increase. The company also saw a substantial improvement in profitability, with a 172.51% increase in profit. The company's net worth moved up by a moderate rise of 6.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unisafe Bioscience?
In 2021, Unisafe Bioscience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Civanta Distributors Private LimitedShabnam Rangwala and Zainab Fatepurwala are mutual person
-
Corogen Pharma Private Limited
Shabnam Rangwala and Zainab Fatepurwala are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Unisafe Bioscience?
Unlock and access historical data on people associated with Unisafe Bioscience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unisafe Bioscience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unisafe Bioscience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
